Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.34 |
| ▸ | LMNA | P02545 | 3/20 | 0.33 |
| ▸ | CNR1 | P21554 | 3/20 | 0.33 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 3/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4134986 | 0.83 | SMN1; SMN2 (0.36) | MAPTCNR1ALDH1A1NPSR1TP53 | |
| SCHEMBL4120953 | 0.82 | MAPT (0.34) | MAPTRIPK1ALDH1A1NPSR1CNR2 | |
| SCHEMBL3700342 | 0.82 | RIPK1 (0.32) | MAPTRIPK1ALDH1A1NPSR1TP53 | |
| SCHEMBL4131694 | 0.81 | KCNQ3 (0.36) | CNR1RIPK1POLBTP53NPC1 | |
| SCHEMBL3693917 | 0.81 | RIPK1 (0.32) | MAPTRIPK1ALDH1A1NPSR1 | |
| SCHEMBL4125768 | 0.80 | ATM (0.35) | MAPTCNR1RIPK1NPC1RAB9A | |
| SCHEMBL3700345 | 0.79 | MAPT (0.32) | MAPTALDH1A1NPSR1TP53CNR2 | |
| SCHEMBL4130901 | 0.78 | TP53 (0.34) | MAPTLMNATP53 | |
| SCHEMBL2836132 | 0.78 | RIPK1 (0.36) | MAPTCNR1RIPK1ALDH1A1NPSR1 | |
| SCHEMBL2838319 | 0.77 | THRB (0.43) | MAPTLMNAALDH1A1NPSR1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2190822-B1 | 5-MEMBERED HETEROCYCLIC COMPOUNDS AS PROTON PUMP INHIBITORS | TAKEDA PHARMACEUTICAL (JP) | 2014-12-31 | — | — | EP | disclosed |
| US-20090156642-A1 | 5-Membered heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156642-A1 | 5-Membered heterocyclic compound | CEL, PGA5, COG5 | MAPT 4258/4885LMNA 4283/4885CNR1 938/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.